About Semaglutide

Semaglutide is a GLP-1 receptor agonist that stimulates insulin production and inhibits glucagon secretion, reducing appetite and food intake. Semaglutide was initially approved for marketing as a therapeutic drug for type 2 diabetes (trade name: Ozempic）， Due to its significant effect in weight loss, the FDA approved its use in the treatment of ordinary obese patients in June 2021 (trade name: Wegovy）， It is the first new drug approved by the US FDA since 2014 for controlling common obesity or overweight. The drug was later approved by the European Union for the treatment of obesity in the same year.